Go to main content
Tricals - The highway towards a cure

Search

Results

centers
University of Sheffield
The Sheffield MND Care and Research Centre provides diagnosis and multi-disciplinary care to patients and carers living with MND and related disorders from a large geographical area of northern England.
centers
University of Milan Medical School
The ALS Centre is a referral center for both the Italian and European ALS patients, being part of the ERN EURO-NMD.
specialists
Vincenzo Silani
Professor of Neurology and Director of the Department of Neuroscience and ALS Centre
specialists
Nicola Ticozzi
Professor of Neurology and Chairman Department of Neurology
specialists
Alberto Doretti
specialists
Claudia Morelli
page
Register
Taking part in the TRICALS registry as a patient will contribute to important research on ALS/MND. This form is intended to create a new account in the TRICALS registry. You will be asked to share your personal contact information. This will allow us to include you in the TRICALS registry. Providing this information is...
news
Results of TUDCA-study: No effect of investigated compound

The TUDCA-ALS consortium has announced the first findings of the TUDCA study, a phase 3 trial investigating the drug TUDCA in individuals with ALS. Unfortunately, the results have showed that taking the drug did not slow down the disease progression.

specialists
Sarsha Wilson
news
Amylyx: no effect after analyzing phase 3 study

The pharmaceutical company Amylyx announced the first results of the PHOENIX study. After analysis, the research drug AMX0035 unfortunately shows no effect in the treatment of ALS.

news
Tofersen receives positive opinion from CHMP (EMA)

The Committe of Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a marketing authorization for QALSODY (better known as Tofersen). If authorized by the European Commission (EC), QALSODY (Tofersen) will be approved in the European Union as a tr...

news
Results ADORE study: no effect of medication

The pharmaceutical company Ferrer has announced their first results of the ADORE clinical trial. Unfortunately, analysis of data showed that the investigated drug edaravone was not effective.